The FDA wants pro-life states to keep waiting
For 26 years, the U.S. Food and Drug Administration has delayed safety reviews for the dangerous chemical abortion drug mifepristone and defied every attempt to subject the drug to normal medical scrutiny. Still, the FDA claims, as it recently told the 5th Circuit during oral arguments in Louisiana v. FDA, pro-life states such as Louisiana lack standing to sue the agency over its chemical abortion regulations. The FDA wants further to delay scrutiny of its politicized chemical abortion regime.
TL;DR
- The FDA has allegedly delayed safety reviews for the abortion drug mifepristone for 26 years.
- Pro-life states, including Louisiana, are suing the FDA over its relaxed regulations on mifepristone, arguing it facilitates illegal abortions.
- The FDA's current regulations allow mifepristone to be delivered by mail, a change from earlier, stricter protocols.
- The FDA claims pro-life states lack standing to sue over the regulations.
- The mifepristone manufacturer, Danco, argues that Louisiana has not exhausted all avenues for relief directly from the FDA.
- Critics cite the FDA's long delays in responding to previous citizen petitions and congressional requests as evidence that further administrative action would be futile.